A phase II trial of lenvatinib in patients with metastatic colorectal cancer after standard chemotherapy

ABSTRACT: Intervention type:DRUG. Intervention1:Lenvatinib, Dose form:CAPSULE, Route of administration:ORAL, intended dose regimen:24mg of lenvatinib is orally taken once daily for 28 days each course. Primary outcome(s): Disease control rate. Timepoint:Every 4 weeks (4th week, 8th week) until 8 weeks from the starting date of treatment , and every 8 weeks (16th week, 24th week, and so on ) after 9 weeks from the starting date of treatment.

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2612407 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR